Try our beta test site
28 studies found for:    Open Studies | "Neurofibromatosis 1"
Show Display Options
Rank Status Study
21 Recruiting Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
Conditions: Neurofibromatosis Type 1;   Brain Tumor;   Glioma
Interventions: Device: Magnetic Resonance Imaging;   Device: Magnetic Resonance Fingerprinting
22 Recruiting PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Conditions: Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
Intervention: Drug: PLX3397
23 Recruiting Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Conditions: Solid Malignancy;   Solid Tumor
Intervention: Drug: Everolimus
24 Recruiting Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Peripheral Nerve Sheath Tumor;   Neurofibromatosis Type 1;   Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions: Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Quality-of-Life Assessment;   Procedure: Single Photon Emission Computed Tomography
25 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Glioma;   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
26 Not yet recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
27 Recruiting A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Conditions: Solid Tumors;   Lung Cancer
Interventions: Drug: BKM120;   Drug: Everolimus
28 Recruiting Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Condition: Neuroendocrine Tumors
Interventions: Drug: Sunitinib;   Drug: Everolimus;   Procedure: Surgery

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-28) Next Page   
Study has passed its completion date and status has not been verified in more than two years.